Considering the potent super-antigenic toxin and pathogenicity of SEB in S. aureus, and vary resistance strategies under different infection situations, we developed mRNA-based vaccines and antibodies targeting SEB for both prophylactic and therapeutic purposes in varying S. aureus infection conditions. Here, SETBP1 is linked to infection.